» Articles » PMID: 19865091

Vaccines and Autoimmunity

Overview
Specialty Rheumatology
Date 2009 Oct 30
PMID 19865091
Citations 73
Authors
Affiliations
Soon will be listed here.
Abstract

Vaccines have been used for over 200 years and are the most effective way of preventing the morbidity and mortality associated with infections. Like other drugs, vaccines can cause adverse events, but unlike conventional medicines, which are prescribed to people who are ill, vaccines are administered to healthy individuals, thus increasing the concern over adverse reactions. Most side effects attributed to vaccines are mild, acute and transient; however, rare reactions such as hypersensitivity, induction of infection, and autoimmunity do occur and can be severe and even fatal. The rarity and subacute presentation of post-vaccination autoimmune phenomena means that ascertaining causality between these events can be difficult. Moreover, the latency period between vaccination and autoimmunity ranges from days to years. In this article, on the basis of published evidence and our own experience, we discuss the various aspects of the causal and temporal interactions between vaccines and autoimmune phenomena, as well as the possible mechanisms by which different components of vaccines might induce autoimmunity.

Citing Articles

Autoimmune hepatitis under the COVID-19 veil: an analysis of the nature of potential associations.

Yu C, Wang W, Zhang Q, Jin Z Front Immunol. 2025; 16:1510770.

PMID: 39958350 PMC: 11825795. DOI: 10.3389/fimmu.2025.1510770.


Next-generation aluminum adjuvants: Immunomodulatory layered double hydroxide NanoAlum reengineered from first-line drugs.

Su Z, Boucetta H, Shao J, Huang J, Wang R, Shen A Acta Pharm Sin B. 2024; 14(11):4665-4682.

PMID: 39664431 PMC: 11628803. DOI: 10.1016/j.apsb.2024.09.012.


Two Cases of Immune Thrombocytopenia (ITP) Related to Viral Vector Vaccination ChAdOx1-S (AstraZeneca) and a Good Response after Thrombopoietin Receptor Agonist (TPO-RA) Therapy.

Salveridou K, Tzamalis T, Klaiber-Hakimi M, Haase S, Gropper S, Giagounidis A Hematol Rep. 2024; 16(4):585-592.

PMID: 39449300 PMC: 11503447. DOI: 10.3390/hematolrep16040057.


Normocomplementemic Urticarial Vasculitis Following Influenza Vaccination: A Case Report and Review of the Literature.

Mima Y, Ohtsuka T, Ebato I, Nakata Y, Nakazato Y, Norimatsu Y Int Med Case Rep J. 2024; 17:823-829.

PMID: 39359663 PMC: 11446193. DOI: 10.2147/IMCRJ.S483023.


COVID-19 vaccine-associated vasculitis: A systematic review.

Abuhammad A, Albandak M, Ayyad M, Refayeh E, Qawasma B, Hour S SAGE Open Med. 2024; 12:20503121241261165.

PMID: 39224893 PMC: 11367607. DOI: 10.1177/20503121241261165.


References
1.
Lasky T, Terracciano G, Magder L, Koski C, Ballesteros M, Nash D . The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med. 1998; 339(25):1797-802. DOI: 10.1056/NEJM199812173392501. View

2.
Kool M, Soullie T, van Nimwegen M, Willart M, Muskens F, Jung S . Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med. 2008; 205(4):869-82. PMC: 2292225. DOI: 10.1084/jem.20071087. View

3.
. Update: Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine--United States, June 2005-September 2006. MMWR Morb Mortal Wkly Rep. 2006; 55(41):1120-4. View

4.
Stassen P, Sanders J, Kallenberg C, Stegeman C . Influenza vaccination does not result in an increase in relapses in patients with ANCA-associated vasculitis. Nephrol Dial Transplant. 2007; 23(2):654-8. DOI: 10.1093/ndt/gfm640. View

5.
Asa P, Cao Y, Garry R . Antibodies to squalene in Gulf War syndrome. Exp Mol Pathol. 2000; 68(1):55-64. DOI: 10.1006/exmp.1999.2295. View